Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Product Portfolio
REGN logo

Regeneron Navigates 42% EYLEA Sales Decline Through Strategic Diversification

REGN10-KFiling Date: 2/4/2026
Regeneron Pharmaceuticals, Inc.
Description

What this story covers

Regeneron’s 2025 10-K highlights a pivotal transition as biosimilar competition eroded flagship EYLEA sales by 42 percent. The company is countering this through robust Dupixent growth, aggressive R&D in oncology and genetics, and significant manufacturing expansions to ensure long-term resilience.

Story snapshot

CompanyRegeneron Pharmaceuticals, Inc.
TickerREGN
VariantStandard detailed
Duration13:03
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000872589-26-000008
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in